All studies
AuthorisedTherapeutic exploratory (Phase II)Interventional

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants with Moderate to Severe Atopic Dermatitis

Atopic dermatitis, commonly known as eczema, is a long-term condition that causes itchy, dry, and inflamed skin. This Phase 2 clinical trial is testing an experimental medicine called TRIV-573 to see if it can help adults whose moderate to severe eczema is not well controlled by standard creams. Participants will receive injections under the skin containing either TRIV-573 or a placebo, which is a dummy treatment. Neither you nor the study team will know which one you receive until the trial ends. Over several clinic visits, doctors will examine your skin, run routine blood tests, and monitor your general health to see if the medicine reduces eczema symptoms and works safely. Joining the trial is completely voluntary. The findings from this research could help scientists develop better, longer-lasting treatments for people living with persistent skin conditions in the future.

At a glance

Status
Authorised
Phase
Therapeutic exploratory (Phase II)
Sponsor
Triveni Bio Inc.
Enrolment target
43
Start
20 Oct 2026

What is this study about?

Atopic dermatitis is the most common form of eczema. It causes patches of skin to become red, dry, cracked, and intensely itchy. For many people, everyday moisturisers and steroid creams are not enough to keep flare-ups under control. When eczema is moderate to severe, it can disturb sleep, make daily activities uncomfortable, and have a major impact on emotional wellbeing. Finding new and more effective treatments is an important goal for medical researchers.

This study looks at a new experimental medicine called TRIV-573. It is designed to calm down the inflammation in the immune system that leads to eczema flare-ups. Researchers want to see if receiving regular injections of TRIV-573 directly under the skin helps to clear eczema patches and reduce itching more effectively than a placebo, which is an inactive dummy treatment.

Because this is a Phase 2 study, the medicine has already been through early safety checks in smaller groups of people. Doctors now want to test it in a larger group to see how well it works, determine the right dose, and monitor how the body processes the drug over time. They will also look closely for any unwanted side effects to ensure the treatment is safe for everyday use.

If TRIV-573 proves to be safe and effective, it could eventually offer a valuable new option for adults who struggle to manage their eczema with current treatments. By taking part, participants provide vital information that could shape future eczema care.

Key takeaways

  • Tests a new injection called TRIV-573 for moderate to severe eczema.
  • Compares the active drug against a dummy treatment (placebo).
  • Open to adults aged 18 and over with persistent eczema symptoms.
  • Involves regular clinic visits for injections, skin checks, and blood tests.
  • Participation is voluntary, and you are free to withdraw at any time.

Who may be eligible?

This trial is open to men and women aged 18 and older who have been diagnosed with moderate to severe atopic dermatitis. To take part, your eczema should be active and affecting a noticeable amount of your skin, especially if standard creams or ointments have not provided enough relief.

You might not be eligible if you have other serious skin problems that could make it difficult to evaluate your eczema, or if you have major medical conditions, such as severe heart or kidney disease. Women who are pregnant or breastfeeding are usually unable to join to protect the baby's safety.

The study doctor will carry out a thorough health check, review your medical history, and discuss any other medications you take before deciding together if the trial is right for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with moderate to severe eczema (atopic dermatitis).
  3. My eczema continues to flare up despite using prescribed treatments.
  4. I am comfortable receiving injections just under the skin.
  5. I am able to travel to a study hospital or clinic for regular check-ups.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves several clinic appointments over a period of weeks to months. At your visits, a healthcare professional will give you the study medication as a small injection just under the skin (subcutaneous injection). You will be randomly assigned by a computer to receive either TRIV-573 or an inactive placebo. Regular clinic checks will include skin examinations, blood and urine tests, blood pressure measurements, and heart traces (ECGs). You may also be asked to keep a brief diary of your symptoms and itching. After the treatment period finishes, you will attend follow-up visits so the study doctors can check on your health and ensure there are no lingering side effects.

Potential risks and benefits

A potential benefit of joining is that your eczema symptoms might improve, though this cannot be guaranteed—especially if you receive the placebo injection. You will also receive close, regular health monitoring from skin specialists throughout the trial. The risks include possible side effects from TRIV-573, which may include mild swelling or soreness at the injection site, or other unforeseen reactions. You can change your mind and leave the study at any point without giving a reason, and your regular NHS care will not be affected in any way.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Czechia
  • —
    Unverified
    Poland

Common questions

What is a placebo and why is it used?

A placebo looks just like the real medicine but contains no active ingredients. It helps researchers prove whether any improvements are genuinely caused by TRIV-573 rather than other factors.

Will I know if I am getting the real drug?

No. This is a double-blind trial, which means neither you nor your study doctor will know which injection you receive until the entire study is finished.

How is the medicine given?

It is given as an injection just under the skin, usually in the tummy or thigh, similar to how insulin is administered.

Do I have to pay to take part?

No. All study appointments, health checks, and study treatments are free of charge, and travel expenses are usually covered.

Can I carry on using my regular eczema moisturisers?

Yes, you can usually continue using approved moisturisers, but the study team will give you clear instructions on which medicated creams you must pause during the trial.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.